JAK1 and atopic eczema: Upatinib, the only JAK1 inhibitor approved for the treatment of IBD in China, is also indicated for other IMIDs such as atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with a recommended dosage of 15 mg once daily.